Polymyalgia Rheumatica-Like Syndrome from Checkpoint Inhibitor Therapy

Is checkpoint inhibitor-related polymyalgia rheumatica (PMR) distinct from the classic rheumatic disease, or does it represent new clinical variants with potentially different pathogenesis, clinical course and treatment responsiveness? Rheumatologist/immunologist Cassandra Calabrese, DO, discusses her research, which identified clinical features that are unusual in idiopathic PMR.